Revel Pharmaceuticals is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Revel Pharmaceuticals demonstrated an engineered bacterial enzyme (CMLA) that oxidizes advanced glycation end-products (AGEs) in elderly human tissue, reversing cross-linking damage previously considered irreversible, with Calico collaboration validating the approach.